P65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.

ABSTRACT:

Background

Lung cancer is still the main cause of cancer death worldwide despite the availability of targeted therapies and immune-checkpoint inhibitors combined with chemotherapy. Cancer cell heterogeneity and primary or acquired resistance mechanisms cause the elusive behaviour of this cancer and new biomarkers and active drugs are urgently needed to overcome these limitations. p65BTK, a novel isoform of the Bruton Tyrosine Kinase may represent a new actionable target in non-small cell lung cancer (NSCLC).

Methods

p65BTK expression was evaluated by immunohistochemistry in 382 NSCLC patients with complete clinico-pathological records including smoking habit, ALK and EGFR status, and in metastatic lymph nodes of 30 NSCLC patients. NSCLC cell lines mutated for p53 and/or a co

SUBMITTER: Giordano F 

PROVIDER: S-EPMC6570906 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature